## 3 Results
### Antibiotic Sensitivity Test by Vitek 2 System  
Based on the interpretation guidelines provided by NCCLS ([PERSON], 2020), the Vitek 2 system classified bacterial susceptibility into susceptible, moderate, or resistant categories. According to the results obtained in this study, the identified bacteria showed variable susceptibility to the tested antibiotics. As shown in Table 4, all E. coli isolates were 100% sensitive to ampicillin, piperacillin/tazobactam, cefalotin, cefoxitin, cefrazidime, ceftriaxone, imipenem,  
Figure 1: Samples taken in January 2022 indicated that the largest number of bacteria were isolated from abattoir D.  
\begin{table} \begin{tabular}{c c c c c c c c c c} \hline \hline  & \multicolumn{2}{c}{**Abattoir A**} & \multicolumn{2}{c}{**Abattoir B**} & \multicolumn{2}{c}{**Abattoir C**} & \multicolumn{2}{c}{**Abattoir D**} \\ \cline{2-10}
**Period** & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **Positive** \\ _E. coli_ \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular} & \begin{tabular}{c} **No. of** \\ **E. coli** \\ \end{tabular} & \
\begin{tabular}{c} **Total** \\ **C. coli** \\ \end{tabular} \\ \hline November 2021 & 12 & 0 & 13 & 2 & 12 & 0 & 13 & 3 & 5 (10\%) \\ January 2022 & 12 & 2 & 13 & 3 & 12 & 1 & 13 & 3 & 9 (18\%) \\ March 2022 & 12 & 0 & 13 & 1 & 12 & 0 & 13 & 3 & 4 (8\%) \\ Total & 36 & 2 (5.5\%) & 39 & 6 (15.3\%) & 36 & 1 (2.5\%) & 39 & 9 (25\%) & 18 (12\%) \\ \hline \hline \end{tabular} 
\begin{tabular}{c c c c c c c c c} \hline \hline  & \multicolumn{2}{c}{**Abattoir A**} & \multicolumn{2}{c}{**Abattoir B**} & \multicolumn{2}{c}{**Abattoir C**} & \multicolumn{2}{c}{**Abattoir D**} \\ \cline{2-10}  
**Period** & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **P****Positive** _S. enterica_ \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **P****Positive** _S. enterica_ \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **Samples** \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **P****Positive** _S. enterica_ \\ \end{tabular}  & \ \begin{tabular}{c} **No. of** \\ **P****Positive** _S. enterica_ \\ \end{tabular}  & \begin{tabular}{c} **No. of** \\ **P****Positive** _S. enterica_ \\ \end{tabular}  \\ \hline November 2021 & 12 & 0 & 13 & 0 & 12 & 0 & 13 & 1 (2\%) \\ January 2022 & 12 & 1 & 13 & 0 & 12 & 0 & 13 & 2 & 3 (6\%) \\ March 2022 & 12 & 1 & 13 & 1 & 12 & 0 & 13 & 4 & 6 (12\%) \\ Total & 36 & 2 (5.5\%) & 39 & 1 (2.5\%) & 36 & 0 merropenem, amikacin, tigecycline, nitrofurantoin, and trimethoprim/sulfamethoxazole. However, some E. coli isolates showed a certain degree of resistance to cefpime (16.67%), ciprofloxacin (16.67%), amoxicillin/clavulanic acid (11.11%), and gentamycin (11.11%). _K. pneumoniae_ isolates were 100% resistant to ampicillin, with 16.67% resistance to ceftazidime, trimethoprim/sulfamethoxazole, and 14.29% resistance to tigecycline. On the other hand, all _K. pneumoniae_ isolates were 100% sensitive to the remaining tested antibiotics. Regarding S. enterica, all isolates were resistant to ampicillin, gentamicin, ciprofloxacin, and trimethoprim/sulfamethoxazole, while showing 100% sensitivity to the remaining tested antimicrobial agents. _P.